<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795648</url>
  </required_header>
  <id_info>
    <org_study_id>20-10-6245</org_study_id>
    <nct_id>NCT04795648</nct_id>
  </id_info>
  <brief_title>Spatial Repellents for Vector Control</brief_title>
  <acronym>AEGIS Mali RCT</acronym>
  <official_title>Spatial Repellent Products for Control of Vector Borne Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Notre Dame</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SC Johnson, A Family Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>fhiClinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Malaria Research and Training Center, Bamako, Mali</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic Relief Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Notre Dame</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to demonstrate and quantify the protective efficacy of&#xD;
      a single Spatial Repellent (SR) product, in reducing malaria infection in a human cohort. The&#xD;
      study design will be a prospective cluster Randomized Control Trial (cRCT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children ≥ 6 months to &lt; 10 years of age will be enrolled in a single cohort across 60&#xD;
      clusters (30 clusters per treatment arm). The cohort will be followed for 6 months for&#xD;
      baseline covariate measurements and 24 months with intervention. Blood samples will be taken&#xD;
      once every 4 weeks from all cohort subjects to test for malaria infection and whenever a&#xD;
      subject reports a recent history of fever (within previous 48 hours). Rapid Diagnostic Tests&#xD;
      (RDTs) will be used for point-of-care treatment of positive infections. All positive malaria&#xD;
      infections, clinical and asymptomatic, will be treated. The incidence of malaria infection&#xD;
      will be measured by microscopy and estimated and compared between treatment arms to determine&#xD;
      the benefit of using an SR in an area with high, seasonal transmission of malaria.&#xD;
      Entomological endpoints of exposure risk to mosquitoes will also be measured to identify&#xD;
      entomological correlates of SR efficacy that may be useful for the evaluation of new SR&#xD;
      products.&#xD;
&#xD;
      The SR will be a new formulation of transfluthrin. This active ingredient (AI) is widely used&#xD;
      in mosquito coils and other household pest control products. The new formulation is a passive&#xD;
      emanator that will release the AI over a period of up to four weeks. The emanator will&#xD;
      consist of a pre-treated piece of cellulose acetate, which will be positioned within&#xD;
      consenting households according to manufacturer specifications. The SRs and placebos for this&#xD;
      study will be designed and manufactured by S.C. Johnson, Inc. USA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 8, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study design will be a prospective cluster Randomized Control Trial (cRCT)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of first-time malaria infection (Plasmodium falciparum (Pf)) during intervention period.</measure>
    <time_frame>24 months</time_frame>
    <description>Measured by microscopy in children aged between 6 months to 10 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of overall new Plasmodium falciparum malaria infections during intervention period.</measure>
    <time_frame>24 months</time_frame>
    <description>Measured by microscopy in children aged between 6 months to 10 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of first-time Plasmodium falciparum malaria infections by two age groups (≤ 59 months old; 5 years old to 10 years old).</measure>
    <time_frame>24 months</time_frame>
    <description>Measured by microscopy in children aged between 6 months to 10 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of overall Plasmodium falciparum malaria infections by two age groups (≤ 59 months old; 5 years to 10 years old).</measure>
    <time_frame>24 months</time_frame>
    <description>Measured by microscopy in children aged between 6 months to 10 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anopheline-human contact (indoor and outdoor) using human biting rate (HBR) as an indicator for all anophelines and by anopheline species.</measure>
    <time_frame>24 months</time_frame>
    <description>Measured by human-landing catch (HLC) during 12-h intervals on a quarterly basis during intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anopheline parity rate as an indicator of population age structure for all anophelines and by anopheline species.</measure>
    <time_frame>24 months</time_frame>
    <description>Measured by mosquito ovarian dissections from a sub-sample of anophelines collected during HLC procedures during intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anopheline infectivity using sporozoite rate as an indicator for all anophelines and by anopheline species.</measure>
    <time_frame>24 months</time_frame>
    <description>Measured by laboratory detection of sporozoites in mosquito head-preps from a sub-sample of anophelines collected during HLC and/or CDC-light trap procedures during intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anopheline infectivity using entomological inoculation rate (EIR) as an indicator for all anophelines and by anopheline species.</measure>
    <time_frame>24 months</time_frame>
    <description>Measured by calculating the number of sporozoite-infected anopheline mosquitoes captured per person during intervention period from HLC and/or CDC-light trap procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDC-light trap indoor density for all anophelines and by anopheline species.</measure>
    <time_frame>24 months</time_frame>
    <description>Measured by CDC-light trap collections during 12-h intervals on a monthly basis during intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insecticide resistance.</measure>
    <time_frame>30 months</time_frame>
    <description>Measured by WHO filter paper test and CDC bottle assays during baseline and intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Serious Adverse Events.</measure>
    <time_frame>30 months</time_frame>
    <description>Measured by solicited and unsolicited reports during baseline and intervention period. Mean, minimum and maximum frequency and percentage of Adverse Events(AEs) and Severe Adverse Events (SAEs) across clusters among enrolled subjects will be summarized by treatment arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1920</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Spatial Repellent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfluthrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inert ingredients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transfluthrin</intervention_name>
    <description>Passive emanator with formulated transfluthrin</description>
    <arm_group_label>Spatial Repellent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Passive emanator with formulated inert ingredients</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children ≥ 6 months to &lt; 10 years of age&#xD;
&#xD;
          -  Children with Hb &gt; 7 mg/dL and no other serious illness&#xD;
&#xD;
          -  Sleeps in cluster ≥ 90% of nights during any given month&#xD;
&#xD;
          -  Not participating in another clinical trial investigating a vaccine, drug, medical&#xD;
             device, or a medical procedure during the trial&#xD;
&#xD;
          -  Provision of informed consent (and/or assent) form (ICF) signed by the parent(s) or&#xD;
             guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children &lt; 6 months or ≥ 10 years&#xD;
&#xD;
          -  Children with Hb ≤ 7 mg/dL, or Hb &lt; 6mg/dL with signs of clinical decompensation and&#xD;
             no other serious illness&#xD;
&#xD;
          -  Sleeps in cluster &lt;90% of nights during any given month&#xD;
&#xD;
          -  Participating or planned participation in another clinical trial investigating a&#xD;
             vaccine, drug, medical device, or a medical procedure during the trial&#xD;
&#xD;
          -  No provision of ICF (and/or assent) signed by the parent(s) or guardian&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Grieco, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Notre Dame</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suzanne Van Hulle, M.H.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic Relief Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic Relief Services</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malaria Research and Training Center (MRTC), University of Bamako, Mali</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mali</country>
  </location_countries>
  <link>
    <url>http://www.sante.gov.ml/index.php/annuaires/download/4-systeme-local-d-information-sanitaire-slis/6-annuaire-statistique-2018-du-systeme-local-d-information-sanitaire-du-mali</url>
    <description>Annuaire Statistique 2018 du Systeme Local d'Information Sanitaire (SLIS) du Mali, 2018</description>
  </link>
  <link>
    <url>https://dhsprogram.com/pubs/pdf/SR261/SR261.E.pdf</url>
    <description>Demographic Health Survey, Mali, 2018</description>
  </link>
  <link>
    <url>https://dhsprogram.com/what-we-do/survey/survey-display-487.cfm</url>
    <description>Demographic Health Survey, Mali, 2015</description>
  </link>
  <link>
    <url>https://www.dhis2.org/about</url>
    <description>Health Management Information System, DHIS2, 2018</description>
  </link>
  <link>
    <url>https://catalog.ihsn.org/index.php/catalog/4569</url>
    <description>Recensement General de la Population et de l'Habitat du Mali (RGPH) 2009</description>
  </link>
  <reference>
    <citation>Achee NL, Bangs MJ, Farlow R, Killeen GF, Lindsay S, Logan JG, Moore SJ, Rowland M, Sweeney K, Torr SJ, Zwiebel LJ, Grieco JP. Spatial repellents: from discovery and development to evidence-based validation. Malar J. 2012 May 14;11:164. Review.</citation>
    <PMID>22583679</PMID>
  </reference>
  <reference>
    <citation>Cisse MB, Keita C, Dicko A, Dengela D, Coleman J, Lucas B, Mihigo J, Sadou A, Belemvire A, George K, Fornadel C, Beach R. Characterizing the insecticide resistance of Anopheles gambiae in Mali. Malar J. 2015 Aug 22;14:327. doi: 10.1186/s12936-015-0847-4.</citation>
    <PMID>26296644</PMID>
  </reference>
  <reference>
    <citation>Fanello C, Petrarca V, della Torre A, Santolamazza F, Dolo G, Coulibaly M, Alloueche A, Curtis CF, Touré YT, Coluzzi M. The pyrethroid knock-down resistance gene in the Anopheles gambiae complex in Mali and further indication of incipient speciation within An. gambiae s.s. Insect Mol Biol. 2003 Jun;12(3):241-5.</citation>
    <PMID>12752657</PMID>
  </reference>
  <reference>
    <citation>Hill N, Zhou HN, Wang P, Guo X, Carneiro I, Moore SJ. A household randomized, controlled trial of the efficacy of 0.03% transfluthrin coils alone and in combination with long-lasting insecticidal nets on the incidence of Plasmodium falciparum and Plasmodium vivax malaria in Western Yunnan Province, China. Malar J. 2014 May 31;13:208. doi: 10.1186/1475-2875-13-208.</citation>
    <PMID>24885993</PMID>
  </reference>
  <reference>
    <citation>Kawada H, Temu EA, Minjas JN, Matsumoto O, Iwasaki T, Takagi M. Field evaluation of spatial repellency of metofluthrin-impregnated plastic strips against Anopheles gambiae complex in Bagamoyo, coastal Tanzania. J Am Mosq Control Assoc. 2008 Sep;24(3):404-9.</citation>
    <PMID>18939693</PMID>
  </reference>
  <reference>
    <citation>Keïta M, Traoré S, Sogoba N, Dicko AM, Coulibaly B, Sacko A, Doumbia S, Traoré SF. [Susceptibility status of Anopheles gambiae sensu lato to insecticides commonly used for malaria control in Mali]. Bull Soc Pathol Exot. 2016 Feb;109(1):39-45. doi: 10.1007/s13149-015-0461-2. Epub 2016 Jan 6. French.</citation>
    <PMID>26740098</PMID>
  </reference>
  <reference>
    <citation>Lucas JR, Shono Y, Iwasaki T, Ishiwatari T, Spero N, Benzon G. U.S. laboratory and field trials of metofluthrin (SumiOne) emanators for reducing mosquito biting outdoors. J Am Mosq Control Assoc. 2007 Mar;23(1):47-54.</citation>
    <PMID>17536367</PMID>
  </reference>
  <reference>
    <citation>Ogoma SB, Moore SJ, Maia MF. A systematic review of mosquito coils and passive emanators: defining recommendations for spatial repellency testing methodologies. Parasit Vectors. 2012 Dec 7;5:287. doi: 10.1186/1756-3305-5-287. Review.</citation>
    <PMID>23216844</PMID>
  </reference>
  <reference>
    <citation>Syafruddin D, Bangs MJ, Sidik D, Elyazar I, Asih PB, Chan K, Nurleila S, Nixon C, Hendarto J, Wahid I, Ishak H, Bøgh C, Grieco JP, Achee NL, Baird JK. Impact of a spatial repellent on malaria incidence in two villages in Sumba, Indonesia. Am J Trop Med Hyg. 2014 Dec;91(6):1079-87. doi: 10.4269/ajtmh.13-0735. Epub 2014 Oct 13.</citation>
    <PMID>25311699</PMID>
  </reference>
  <reference>
    <citation>Tripet F, Wright J, Cornel A, Fofana A, McAbee R, Meneses C, Reimer L, Slotman M, Thiemann T, Dolo G, Traoré S, Lanzaro G. Longitudinal survey of knockdown resistance to pyrethroid (kdr) in Mali, West Africa, and evidence of its emergence in the Bamako form of Anopheles gambiae s.s. Am J Trop Med Hyg. 2007 Jan;76(1):81-7.</citation>
    <PMID>17255234</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>Spatial Repellent</keyword>
  <keyword>Transfluthrin</keyword>
  <keyword>Vector-borne diseases</keyword>
  <keyword>Mosquito vectors</keyword>
  <keyword>Incidence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Vector Borne Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Analytical datasets will be anonymized and GPS tag-blurred to remove sensitive information prior to sharing.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data and supporting information will be made available 12 months following completion of data analysis and will remain open access in the public domain.</ipd_time_frame>
    <ipd_access_criteria>Open-access repository distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

